Pay in 4 interest-free payments of $7.22 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
Full disclaimer 1.Retatrutide (LY3437943) is a first-in-class triple agonist targeting GLP-1, GIP, and glucagon receptors, developed by Eli Lilly 2.Phase 2 trials demonstrated up to 24.2% body weight loss at 48 weeksthe highest weight loss ever reported in a Phase 2 obesity trial 3.Triple mechanism activates multiple metabolic pathways: appetite suppression (GLP-1), improved insulin sensitivity (GIP), and increased energy expenditure (glucagon) 4.Currently in Phase 3 TRIUMPH trials for weight management, type 2 diabetes, NASH, and osteoarthritis
It is a sympathomimetic amine (stimulant), anorectic (appetite suppressant), and has a similar mechanism of action as amphetamines (which stimulate the release of epinephrine and norepinephrine)
BPC-157, or Body Protection Compound-157, is a peptide derived from a protein found in the gastric juice
Hashimoto's thyroiditis is not listed as a contraindication to Wegovy treatment in the current Summary of Product Characteristics (SmPC) approved by the MHRA
Companies selling hyperpalatable, calorie-dense products face structural headwinds
US$ 28.95
US$ 21.12
US$ 22.33
US$ 22.23
US$ 29.28
US$ 24.06
